I did some valuations estimates to figure if the Demerger/sale offers a ‘special situations’ kind of opportunity and my conclusion was that the Indian business is currently trading around 19-20 X EBITDA multiple, which is on the lower end of the Hospital Valuations.
If because of demerger, the multiple were to expand to say 25X, this could be an interesting bet, this is when we totally ignore the implicit growth possibilities that may come because of further investments / focus on the Indian business.
Would love to hear thoughts/feedback on the above, thanks
| Subscribe To Our Free Newsletter |
